Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / EktaH

Clinicaltrial registered20 Oct 2026

EktaH

20 Oct 2026: Trial registered · A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS.. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
20 Oct 2026
Title
A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS.
Conditions
Obesity / Overweight, Obesity (BMI Equal to or >30)
Phase
Phase 2
Study Type
Interventional
Status
Not Yet Recruiting
Countries
Tunisia
Country
Tunisia
Reference
NCT07882654
Location
Tunisia
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at EktaH

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for EktaH in our registers.

More from Tunisia

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.